{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:25:27Z","timestamp":1759541127234},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Gefitinib and erlotinib have minor differences in their chemical structures, and thus it remains unclear whether the hepatotoxicity induced by one compound is affected by the other. The case of a patient who developed erlotinib-induced liver injury and was then treated with gefitinib without hepatic toxicity or disease progression is presented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 31-year-old Japanese woman, who never smoked and who was diagnosed as having lung adenocarcinoma with carcinomatous meningitis, was treated with erlotinib. She developed erlotinib-induced liver injury after four weeks of treatment. The treatment was stopped right away, but the symptoms of meningitis re-appeared immediately. Gefitinib treatment was started and continued without recurrence of drug-induced liver injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Gefitinib appears to be a potential treatment option after erlotinib-induced liver injury.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1752-1947-5-593","type":"journal-article","created":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T19:15:43Z","timestamp":1324494943000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment with gefitinib after erlotinib-induced liver injury: a case report"],"prefix":"10.1186","volume":"5","author":[{"given":"Katsumi","family":"Nakatomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iida","family":"Tetsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,21]]},"reference":[{"key":"1996_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1634\/theoncologist.10-8-579","volume":"10","author":"WS Siegel-Lakhai","year":"2005","unstructured":"Siegel-Lakhai WS, Beijnen JH, Schellens JH: Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist. 2005, 10: 579-589. 10.1634\/theoncologist.10-8-579.","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"1996_CR2","doi-asserted-by":"publisher","first-page":"ii46","DOI":"10.1093\/annonc\/mdj921","volume":"17","author":"T Cascone","year":"2006","unstructured":"Cascone T, Morelli MP, Ciardiello F: Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol. 2006, 17 (Suppl 2): ii46-48. 10.1093\/annonc\/mdj921.","journal-title":"Ann Oncol"},{"key":"1996_CR3","first-page":"O-184","volume":"50","author":"Y Inoue","year":"2010","unstructured":"Inoue Y, Fukuoka , Kudoh S, Ando M, Ohe Y, Nakagawa K, Arakawa H, Ebina M, Kiyohara Y, Kusumoto M, Kuwano K, Gemma Y, Sakai F, Johkoh T, Taniguchi H, Fukuda Y, Yamasaki N, Takemoto S, Akiyama : Tarceva Tablet Non-small Cell Lung Cancer Special Drug Use-results Survey Final Analysis about Targeted Numbers (3000 pts) [abstract]. Proc Japan Lung Cancer Society. 2010, 50: O-184-in Japanese","journal-title":"Proc Japan Lung Cancer Society"},{"key":"1996_CR4","first-page":"772","volume":"41","author":"S Yoshida","year":"2005","unstructured":"Yoshida S: The results of gefitinib prospective investigation. Med Drug J. 2005, 41: 772-789. in Japanese","journal-title":"Med Drug J"},{"key":"1996_CR5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","volume":"34","author":"J Ling","year":"2006","unstructured":"Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, Prakash C: Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermalgrowth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006, 34: 420-426.","journal-title":"Drug Metab Dispos"},{"key":"1996_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00498250400026464","volume":"35","author":"D McKillop","year":"2005","unstructured":"McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, Hutchison M: Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica. 2005, 35: 39-50. 10.1080\/00498250400026464.","journal-title":"Xenobiotica"},{"key":"1996_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yrtph.2009.03.003","volume":"54","author":"JI Papay","year":"2009","unstructured":"Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM: Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009, 54: 84-90. 10.1016\/j.yrtph.2009.03.003.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1996_CR8","unstructured":"Drug-Induced Liver Injury: Premarketing Clinical Evaluation. FDA Draft Concept Paper. 2007,http:\/\/www.fda.gov\/cder\/guidance\/7507dft.html"},{"key":"1996_CR9","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1200\/JCO.2009.26.5496","volume":"28","author":"M Takeda","year":"2010","unstructured":"Takeda M, Okamoto I, Fukuoka M, Nakagawa K: Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol. 2010, 28: e273-274. 10.1200\/JCO.2009.26.5496.","journal-title":"J Clin Oncol"},{"key":"1996_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.lungcan.2010.08.012","volume":"70","author":"GY Ku","year":"2010","unstructured":"Ku GY, Chopra A, Lopes Gde L: Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer. 2010, 70: 223-225. 10.1016\/j.lungcan.2010.08.012.","journal-title":"Lung Cancer"},{"key":"1996_CR11","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","volume":"13","author":"J Li","year":"2007","unstructured":"Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007, 13: 3731-3737. 10.1158\/1078-0432.CCR-07-0088.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-5-593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-5-593\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-5-593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-5-593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:29:54Z","timestamp":1630520994000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-5-593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1996"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-5-593","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"31 August 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"593"}}